Dapagliflozin Management Guidelines
Introduction to Dapagliflozin
- The American College of Cardiology recommends monitoring patients taking dapagliflozin annually for kidney function through eGFR and urinary albumin:creatinine ratio assessment, and educating them about potential side effects including genital mycotic infections, urinary tract infections, and diabetic ketoacidosis 1
Dosing and Administration
- Initial dosing of dapagliflozin is 5 mg orally once daily for glycemic control, which can be increased to 10 mg once daily for additional glycemic control and for cardiovascular and kidney protection 1
- The American Journal of Kidney Diseases recommends not using dapagliflozin for glycemic control in patients with eGFR <45 mL/min/1.73m², but it can be used for cardiovascular and kidney protection with eGFR as low as 20-30 mL/min/1.73m² 1, 2, 3
Contraindications and Precautions
- Dapagliflozin is not recommended for patients with severe kidney impairment (eGFR <45 mL/min/1.73m²) for glycemic control, but can be used with caution for cardiovascular and kidney protection 1, 2, 3
- Discontinue dapagliflozin when dialysis is initiated, although limited evidence suggests it may be safe in dialysis patients 3
Benefits and Efficacy
- Dapagliflozin reduces the risk of cardiovascular death and hospitalization for heart failure, sustained eGFR decline and kidney failure, particularly in patients with eGFR ≥20 mL/min/1.73m² and urinary albumin:creatinine ratio ≥200 mg/g 1, 2, 3
Monitoring and Management
- Annual screening for kidney disease (eGFR and urinary albumin:creatinine ratio) is recommended for patients taking dapagliflozin 2
- Monitor patients for signs of volume depletion, urinary tract infections, genital mycotic infections, and diabetic ketoacidosis, particularly during acute illness or fasting 3, 4
- Educate patients on genital hygiene, sick day management protocol, recognition of DKA symptoms, importance of adequate hydration, and self-monitoring for signs of urinary tract infections 3, 4, 5
Adverse Effects
- Genital mycotic infections are the most common adverse effect of dapagliflozin, particularly in women, and can be mitigated with education on genital hygiene 3
- Urinary tract infections and diabetic ketoacidosis are rare but serious adverse effects that require prompt medical attention 4
Special Considerations
- Dapagliflozin may facilitate the use of other guideline-directed therapies (RAS inhibitors, mineralocorticoid receptor antagonists) by reducing hyperkalemia risk 3
- Consider reducing doses of insulin or insulin secretagogues when used with dapagliflozin to reduce hypoglycemia risk 3